Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2014 | ASH 2014: The management of CLL

George Follows • 9 Apr 2015
ASH 2014
Chronic Lymphocytic Leukemia

Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularity defined subtypes in CLL.

More from George Follows

Five-year follow up of the UK CLL Forum ibrutinib data
3:58
Five-year follow up of the UK CLL Forum ibrutinib data
George Follows • 20 Sep 2019
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
PEP-C for treatment of relapsed/refractory lymphoma
1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
MURANO study: exciting times in CLL
2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals